Verve Therapeutics

VERV41

$5.59arrow_drop_up1.17%$0.06

VERV41

$5.59

arrow_drop_up1.17%$0.06

Performance History

Key Stats
Open	$5.54
Prev. Close	$5.53
EPS	-2.59
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	5.15	5.73
52 Week Range	4.30	20.12

Ratios







EPS	-2.59

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Verve Therapeutics (VERV)

Verve Therapeutics, Inc. (VERV) is a biotechnology company that is focused on developing transformative medicines to treat cardiovascular diseases. With a mission to prevent cardiovascular disease through gene editing, Verve Therapeutics is at the forefront of innovative therapies that have the potential to revolutionize the field of medicine. The company is dedicated to harnessing the power of gene editing to address the underlying genetic causes of cardiovascular diseases, such as heart attacks and strokes.

One of the key drivers of Verve Therapeutics' success is its commitment to smart analysis. By leveraging cutting-edge technologies and advanced data analytics, the company is able to gain valuable insights into the genetic factors that contribute to cardiovascular diseases. This smart analysis allows Verve Therapeutics to identify key targets for gene editing and develop precision therapies that have the potential to transform the lives of patients.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Headquarters: Cambridge
Employees: 204
Exchange: NASDAQ

Keep an eye on Verve Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Verve Therapeutics's (VERV) price per share?

The current price per share for Verve Therapeutics (VERV) is $5.6. The stock has seen a price change of $0.06 recently, indicating a 1.18% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Verve Therapeutics (VERV)?

For Verve Therapeutics (VERV), the 52-week high is $20.12, which is 259.61% from the current price. The 52-week low is $4.3, the current price is 29.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Verve Therapeutics (VERV) a growth stock?

Verve Therapeutics (VERV) has shown an average price growth of 0.41% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Verve Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Verve Therapeutics (VERV) stock price performance year to date (YTD)?

As of the latest data, Verve Therapeutics (VERV) has a year-to-date price change of -60.04%. Over the past month, the stock has experienced a price change of -8.28%. Over the last three months, the change has been 5.97%. Over the past six months, the figure is -62.87%.

help

Is Verve Therapeutics (VERV) a profitable company?

Verve Therapeutics (VERV) has a net income of -$200.07M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 53.61% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -879.24% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $11.76M, although specific revenue growth data is currently not available. The gross profit is $6.3M. Operating income is noted at -$223.12M. Furthermore, the EBITDA is -$215.68M.

help

What is the market capitalization of Verve Therapeutics (VERV)?

Verve Therapeutics (VERV) has a market capitalization of $467.97M. The average daily trading volume is 1.69M, indicating the stock's liquidity and investor engagement.

News

VERVE THERAPEUTICS

SECURITIES CLASS ACTION

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV

VERV Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the Verve Therapeutics, Inc. Class Action

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

VERVE THERAPEUTICS

SECURITIES CLASS ACTION

CLINICAL TRIAL

PRODUCT DEVELOPMENT

9/1/2024

רוזן, פירמת עורכי דין גלובלית ומובילה, מעודדת את משקיעי Verve Therapeutics, Inc לקבל ייעוץ לפני תאריך יעד חשוב בתביעה ייצוגית בניירות ערך שהוגשה לראשונה על ידי המשרד – VERV

VERVE THERAPEUTICS

SECURITIES CLASS ACTION

VERVE-101

HEART-1 PHASE 1B CLINICAL TRIAL

LIPID NANOPARTICLE (LNP) DELIVERY SYSTEM

9/1/2024

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm